AbCellera Biologics (STU:8QQ) Net Cash per Share : €1.14 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). AbCellera Biologics's Net Cash per Share for the quarter that ended in Mar. 2024 was €1.14.

The historical rank and industry rank for AbCellera Biologics's Net Cash per Share or its related term are showing as below:

STU:8QQ' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.91 Med: 5 Max: 25.79
Current: 3.03

During the past 6 years, the highest Price-to-Net-Cash Ratio of AbCellera Biologics was 25.79. The lowest was 2.91. And the median was 5.00.

STU:8QQ's Price-to-Net-Cash is ranked better than
60.58% of 855 companies
in the Biotechnology industry
Industry Median: 4.05 vs STU:8QQ: 3.03

AbCellera Biologics Net Cash per Share Historical Data

The historical data trend for AbCellera Biologics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Net Cash per Share Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

Get a 7-Day Free Trial

-0.02

1.28

1.34

1.90

1.34

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Cash per Share	Get a 7-Day Free Trial															1.64	1.46	1.48	1.34	1.14

Competitive Comparison of AbCellera Biologics's Net Cash per Share

For the Biotechnology subindustry, AbCellera Biologics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbCellera Biologics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Price-to-Net-Cash falls into.

AbCellera Biologics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

AbCellera Biologics's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(697.456	-	307.907	-	0)	/	290.825
=	1.34

AbCellera Biologics's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

	Net Cash per Share (Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(642.181	-	306.528	-	0)	/	293.621
=	1.14

AbCellera Biologics (STU:8QQ) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

AbCellera Biologics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics (STU:8QQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

ABCL:USA

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics (STU:8QQ) Headlines

No Headlines